You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 29, 2024

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Heparin Sodium 25,000 Units In Dextrose 5% patents expire, and when can generic versions of Heparin Sodium 25,000 Units In Dextrose 5% launch?

Heparin Sodium 25,000 Units In Dextrose 5% is a drug marketed by Fresenius Kabi Usa, Hospira, and B Braun. and is included in six NDAs.

The generic ingredient in HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% is heparin sodium. There are seventy-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Heparin Sodium 25,000 Units In Dextrose 5%

A generic version of HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% was approved as heparin sodium by HOSPIRA on April 28th, 1983.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%?
  • What are the global sales for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%?
  • What is Average Wholesale Price for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%?
Summary for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
Drug patent expirations by year for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%
Recent Clinical Trials for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vaneltix Pharma, Inc.Phase 2
Prevail Infoworks, IncPhase 2
The First Affiliated Hospital with Nanjing Medical UniversityN/A

See all HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% clinical trials

Pharmacology for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

US Patents and Regulatory Information for HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% heparin sodium INJECTABLE;INJECTION 017029-022 Aug 24, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
B Braun HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER heparin sodium INJECTABLE;INJECTION 019952-005 Jul 20, 1992 AP RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hospira HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% heparin sodium INJECTABLE;INJECTION 018911-008 Jan 30, 1985 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hospira HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER heparin sodium INJECTABLE;INJECTION 019339-004 Mar 27, 1985 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Fresenius Kabi Usa HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% heparin sodium INJECTABLE;INJECTION 017029-023 Aug 24, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.